Updates on hepatorenal syndrome and strategies bridging to liver transplantation

Abstract

Hepatorenal syndrome is not an uncommon life-threatening complication arising from liver cirrhosis. The diagnostic criteria for this syndrome have been revised throughout the years, with recent revisions aimed at improving earlier diagnosis and treatment. Liver transplantation remains the only definitive treatment for hepatorenal syndrome. Due to the scarcity of liver grafts, many patients die waiting. This review focuses on the different strategies to bridge patients to liver transplantation and to improve the postoperative outcome.

Keywords

Hepatorenal syndrome / liver cirrhosis / terlipressin / liver transplantation / portal hypertension / acute kidney injury

References

[1] Erly B,Kapoor B,Tam M.Hepatorenal syndrome: a review of pathophysiology and current treatment options..Semin Intervent Radiol2015;32:445-54 PMCID:PMC4640915

[2] Baraldi O,Donati G,Cuna V,Angelini ML,Angeletti A,La Manna G.Hepatorenal syndrome: update on diagnosis and treatment..World J Nephrol2015;4:511-20 PMCID:PMC4635371

[3] Gines P,Arroyo V.Hepatorenal syndrome..Lancet2003;29:1819-27

[4] Pillebout E.Hepatorenal syndrome..Nephrol Ther2014;10:61-8

[5] Arroyo V,Gerbes AL,Gentilini P,Reynolds TB,Scholmerich J.Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club..Hepatology1996;23:164-76

[6] Bittencourt PL,Terra C.Renal failure in cirrhosis: emerging concepts..World J Hepatol2015;7:2336-43 PMCID:PMC4577641

[7] Salerno F,Gines P,Arroyo V.Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis..Gut2007;56:1310-8

[8] Angeli P.Optimal management of hepatorenal syndrome in patients with cirrhosis..Hepat Med2010;2:87-98 PMCID:PMC3846372

[9] Rodriguez E,Sola E,Barreto R,Colmenero J,Navasa M,Gines P.Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: effects on kidney function and transplantation outcomes..Liver Transpl2015;21:1347-54

[10] Angeli P,Wong F,Boyer TD,Moreau R,Sarin SK,Moore K,Durand F,Caraceni P,Arroyo V,International Club of Ascites..Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites..Gut2015;64:531-7

[11] Boyer TD,Garcia-Tsao G,Carl D,Teuber P.Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics..J Hepatol2011;55:315-21 PMCID:PMC3728672

[12] Moller S,Bendtsen F.Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes..Liver Int2014;34:1153-63

[13] Rice JP,Said A.Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin..Transplantation2011;91:1141-7

[14] Le Moine O,Jagodzinski R,Adler M,Cremer M.Treatment with terlipressin as a bridge to liver transplantation in a patient with hepatorenal syndrome..Acta Gastroenterol Belg1998;61:268-70

[15] Gluud LL,Christensen E.Terlipressin for hepatorenal syndrome..Cochrane Database Syst Rev2012;9:CD005162

[16] Sola E,Gines P.Results of pretransplant treatment of hepatorenal syndrome with terlipressin..Curr Opin Organ Transplant2013;18:265-70

[17] Garcia-Martinez R,Bernardi M,Arroyo V.Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications..Hepatology2013;58:1836-46

[18] Boyer TD,Wong F,Lake JR,Ganger D,Pappas SC.Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1..Gastroenterology2016;150:1579-89.e2

[19] Salerno F,Wilkes MM.Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis..BMC Gastroenterol2015;15:167 PMCID:PMC4660686

[20] Cort JH,Novakova J,Jost K.Regional and systemic haemodynamic effects of some vasopressins: structural features of the hormone which prolong activity..Eur J Clin Invest1975;5:165-75

[21] Moller S,Becker U,Henriksen JH.Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients..Liver2000;20:51-9

[22] Barbano B,Gigante A,Liberatori M,Lacanna A,Cianci R.Pathophysiology, diagnosis and clinical management of hepatorenal syndrome: from classic to new drugs..Curr Vasc Pharmacol2014;12:125-35

[23] Gluud LL,Christensen E.Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome..Hepatology2010;51:576-84

[24] Cavallin M,Romano A,Frigo AC,Gola E,Stanco M,Sticca A,Angeli P.Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study..Hepatology2016;63:983-92

[25] Velez JC.Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials..Am J Kidney Dis2011;58:928-38 PMCID:PMC3251915

[26] Duvoux C,Hezode C,Monin JL,Mallat A.Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study..Hepatology2002;36:374-80

[27] Nassar Junior AP,D' Albuquerque LA,Malbouisson LM.Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis..PLoS One2014;9:e107466

[28] Skagen C,Lucey MR.Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome..J Clin Gastroenterol2009;43:680-5

[29] Siramolpiwat S.Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications..World J Gastroenterol2014;20:16996-7010 PMCID:PMC4258568

[30] Guevara M,Bandi JC,Sort P,Garcia-Pagan JC,Arroyo V.Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems..Hepatology1998;28:416-22

[31] Testino G,Sumberaz A,Morelli N,Ardizzone G.Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation..Hepatogastroenterology2003;50:1753-5

[32] Brensing KA,Perz J,Raab P,Klehr HU,Spengler U,Sauerbruch T.Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study..Gut2000;47:288-95 PMCID:PMC1727992

[33] Wong F,Sniderman K.Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome..Hepatology2004;40:55-64

[34] Martin-Llahi M,Torre A,Restuccia T,Sola E,Marinelli M,Fernandez J,Arroyo V.Prognostic importance of the cause of renal failure in patients with cirrhosis..Gastroenterology2011;140:488-96.e4

[35] Stange J,Risler T,Lauchart W,Klammt S,Freytag J,Lohr M,Schareck W,Schmidt R.Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support..Artif Organs1999;23:319-30

[36] Rahman TM.Review article: liver support systems in acute hepatic failure..Aliment Pharmacol Ther1999;13:1255-72

[37] Mitzner SR,Klammt S,Erley CM,Berger ED,Peszynski P,Hickstein H,Lohr JM,Emmrich J,Schmidt R.Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial..Liver Transpl2000;6:277-86

[38] Arroyo V.New treatments for hepatorenal syndrome..Liver Transpl2000;6:287-9

[39] Chok KS,Chan SC,Sharr WW,Fan ST.Outcomes of living donor liver transplantation for patients with preoperative type 1 hepatorenal syndrome and acute hepatic decompensation..Liver Transpl2012;18:779-85

[40] Gonwa TA,Melton LB,Goldstein RM,Klintmalm GB.End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment..Transplantation2001;72:1934-9

[41] Lee JP,Joo KW,Suh KS,Kim SG.Risk factors for consequent kidney impairment and differential impact of liver transplantation on renal function..Nephrol Dial Transplant2010;25:2772-85

[42] Wong F,Al Beshir M,Renner EL.Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation..Liver Transpl2015;21:300-7

[43] Restuccia T,Guevara M,Alessandria C,Navasa M,Garcia-Valdecasas JC,Rodes J.Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study..J Hepatol2004;40:140-6

[44] Fayed N,Yassein TE.Effect of perioperative terlipressin infusion on systemic, hepatic, and renal hemodynamics during living donor liver transplantation..J Crit Care2013;28:775-82